Last reviewed · How we verify

Teriparatide (rDNA origin)

Bio Sidus SA · FDA-approved active Small molecule

Teriparatide is a recombinant human parathyroid hormone (PTH 1-34) that stimulates osteoblasts to increase bone formation and remodeling.

Teriparatide is a recombinant human parathyroid hormone (PTH 1-34) that stimulates osteoblasts to increase bone formation and remodeling. Used for Osteoporosis in postmenopausal women at high risk of fracture, Osteoporosis in men at high risk of fracture, Glucocorticoid-induced osteoporosis.

At a glance

Generic nameTeriparatide (rDNA origin)
SponsorBio Sidus SA
Drug classParathyroid hormone analog
TargetPTH1 receptor (PTHR1)
ModalitySmall molecule
Therapeutic areaEndocrinology / Bone Metabolism
PhaseFDA-approved

Mechanism of action

Teriparatide mimics the action of endogenous parathyroid hormone by binding to PTH1 receptors on osteoblasts, promoting bone anabolism and increasing bone mineral density. Unlike continuous PTH exposure (which causes bone loss), intermittent PTH administration preferentially stimulates bone formation over resorption, leading to net increases in bone mass and strength.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: